Thomas Stankovich - 31 Mar 2023 Form 4 Insider Report for ReShape Lifesciences Inc. (RSLS)

Role: Chief Financial Officer
Signature: /s/ Thomas Stankovich
Issuer symbol: RSLS
Transactions as of: 31 Mar 2023
Net transactions value: +$26,161
Form type: 4
Filing time: 06 Jul 2023, 16:16:26 UTC
Previous filing: 07 Mar 2023
Next filing: 19 Jul 2023
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	RSLS	Common Stock, $0.001 par value per share	Sale	$283	-109	-1.8%	$2.60	5,982	31 Mar 2023	Direct	F1
transaction	RSLS	Common Stock, $0.001 par value per share	Sale	$227	-96	-1.6%	$2.36	5,886	30 Apr 2023	Direct	F1
transaction	RSLS	Common Stock, $0.001 par value per share	Sale	$236	-98	-1.7%	$2.41	5,788	31 May 2023	Direct	F1
transaction	RSLS	Common Stock, $0.001 par value per share	Purchase	$26,907	+17,702	+306%	$1.52	23,490	30 Jun 2023	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	On July 22, 2021, Mr. Stankovich was awarded an aggregate of 7,455 restricted stock units, all of which, including the unvested portion, were reported on a Form 4 filed on September 17, 2021. The shares reported under this Form 4 as being disposed of were sold to cover taxes in connection with the vesting of a portion of those previously reported restricted stock units.
F2	The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.45 to $1.54, inclusive. The reporting person undertakes to provide to ReShape Lifesciences Inc., any security holder of ReShape Lifesciences Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (2) to this Form 4.

Content

On July 22, 2021, Mr. Stankovich was awarded an aggregate of 7,455 restricted stock units, all of which, including the unvested portion, were reported on a Form 4 filed on September 17, 2021. The shares reported under this Form 4 as being disposed of were sold to cover taxes in connection with the vesting of a portion of those previously reported restricted stock units.

The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.45 to $1.54, inclusive. The reporting person undertakes to provide to ReShape Lifesciences Inc., any security holder of ReShape Lifesciences Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (2) to this Form 4.